News and Events
Read here about Neurokin's latest news and events:
Subscribe to our comprehensive news feed
The neuroprotective drugs development company announces today the appointment of two former Vice Presidents of Sanofi - Aventis; Bernard Reculeau, and Jesús Benavides.
The Company strengthens its intellectual property with the grant of European patent on its most advanced
drug candidate NK-102.
The significant results obtained by NEUROKIN were published in August by the PLoS One Revue in an article entitled: « Delayed Treatment with Systemic (S)-Roscovitine Provides Neuroprotection and Inhibits In Vivo CDK5 Activity Increase in Animal Stroke Models »*.
Bénédicte Menn et al., PLoS ONE, August 2010, volume 5, issue 8.
Neurokin's patent EP 1 998 778 has been granted.
Neurokin launches updated website.
Bernard Reculeau has been nominated member of the Board of NEUROKIN
The European Patent Office has declared its intention to deliver the patent issued from its application n° 07731236.1.
Neurokin's CEO Jerome Becquart will attend the Bio Convention in Atlanta, May 18-21 2009
